DISTRIBUTION AND SUBLICENSE AGREEMENTDistribution and Sublicense Agreement • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS DISTRIBUTION AND SUBLICENSE AGREEMENT (this “Agreement”), dated as of February 1, 2016 (the “Effective Date”), by and between Braeburn Pharmaceuticals, inc., a corporation formed under the laws of Delaware (“Braeburn”), and Knight Therapeutics Inc., a corporation incorporated under the laws of Canada (“Knight”).
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, the Company and Executive are parties to an employment agreement dated September 29, 2016 (the “Employment Agreement”); and
AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, the Company and Executive are parties to an employment agreement dated September 29, 2016 (the “Employment Agreement”); and
Thirteenth Amendment to Office leaseOffice Lease • August 14th, 2018 • Titan Pharmaceuticals Inc • Biological products, (no disgnostic substances) • California
THIS THIRTEENTH AMENDMENT TO OFFICE LEASE (the “Thirteenth Amendment”) is made and entered into as of March 21, 2016, by and between KASHIWA FUDOSAN AMERICA, INC., a California corporation (“Landlord”) and TITAN PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”).
